KBC Group NV (KBCSY) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4668916-kbc-group-nv-kbcsy-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Feb 08, 2024 - KBC Group NV (OTCPK:KBCSY) Q4 2023 Earnings Conference Call February 8, 2024 3:30 AM ETCompany ParticipantsKurt De Baenst – Investor Relations ManagerJohan...
0
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
0
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fda-s-odac?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221922
Feb 06, 2024 - Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
0
Euronav NV (EURN) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4667181-euronav-nv-eurn-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Feb 02, 2024 - Euronav NV (NYSE:NYSE:EURN) Q4 2023 Earnings Conference Call February 2, 2024 8:00 AM ETCompany ParticipantsAlexander Saverys - Chief Executive...
0
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates
https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214
Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
0
Novartis Ag (NVS) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/01/31/novartis-ag-nvs-q4-2023-earnings-call-transcript/?source=iedfolrf0000001
Jan 31, 2024 - NVS earnings call for the period ending December 31, 2023.
0
Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
https://www.zacks.com/stock/news/2216430/novartis-nvs-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2216430
Jan 26, 2024 - Besides Wall Street's top -and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
0
Top Research Reports for Novartis, Amgen & Palo Alto Networks
https://www.zacks.com/commentary/2214881/top-research-reports-for-novartis-amgen-palo-alto-networks?cid=CS-ZC-FT-research_daily-2214881
Jan 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW).
0
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
0
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
https://www.zacks.com/commentary/2211005/these-stocks-are-showing-relative-strength-as-s-p-500-stalls-near-record-high?cid=CS-ZC-FT-investment_ideas-2211005
Jan 16, 2024 - As investors, our job isn't to predict an unknowable future.
0